株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ホルモン補充療法 (HRT) の世界市場:分析、シェア、動向、規模、予測

Hormone Replacement Therapy (HRT) Market, By Replacement Therapy (Estrogen, Human Growth Hormone, Testosterone and Thyroid), By Route of Administration, By Disease, and Geography - Analysis, Share, Trends, Size, & Forecast From 2014 - 2025

発行 AnalystView Market Insights 商品コード 737898
出版日 ページ情報 英文 109 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=108.97円で換算しております。
Back to Top
ホルモン補充療法 (HRT) の世界市場:分析、シェア、動向、規模、予測 Hormone Replacement Therapy (HRT) Market, By Replacement Therapy (Estrogen, Human Growth Hormone, Testosterone and Thyroid), By Route of Administration, By Disease, and Geography - Analysis, Share, Trends, Size, & Forecast From 2014 - 2025
出版日: 2018年05月15日 ページ情報: 英文 109 Pages
概要

当レポートでは、世界のホルモン補充療法 (HRT) 市場について調査分析し、市場概要、市場動向、産業分析、市場情勢、セグメント別の市場分析、主要ベンダー分析について、体系的な情報を提供しています。

第1章 ホルモン補充療法 (HRT) :市場概要

  • 調査範囲
  • 前提条件と調査手法

第2章 エグゼクティブサマリー

第3章 ホルモン補充療法 (HRT) :主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 ホルモン補充療法 (HRT) :産業分析

  • ファイブフォース分析
  • 市場の魅力分析
  • 規制の枠組み分析

第5章 ホルモン補充療法 (HRT) :市場情勢

  • 市場シェア分析

第6章 ホルモン補充療法 (HRT) 市場:補充療法別

  • 概要
  • エストロゲン
  • ヒト成長ホルモン
  • テストステロン
  • 甲状腺

第7章 ホルモン補充療法 (HRT) 市場:投与経路別

  • 概要
  • 非経口
  • 経口
  • 経皮
  • その他

第8章 ホルモン補充療法 (HRT) 市場:疾患別

  • 男性性腺機能低下症
  • 更年期
  • 甲状腺機能低下症
  • 成長ホルモン欠損症 (GHD)
  • その他

第9章 ホルモン補充療法 (HRT) 市場:地域別

  • イントロダクション
  • 北米
  • 欧州
  • アジア太平洋地域
  • その他の地域

第10章 主要ベンダー分析

  • Novo Nordisk
  • Amgen, Inc.
  • Abbott
  • Eli Lily & Company
  • Genentech

第11章 アナリストの見解

第12章 付録

図表

List of Tables

  • Table 1 List of Acronyms
  • Table 2 Key Market Facts, 2014 - 2025
  • Table 3 Market Drivers: Impact Analysis
  • Table 4 Market Restraint: Impact Analysis
  • Table 5 Market Opportunity: Impact Analysis
  • Table 6 PEST Analysis
  • Table 7 Porter's Five Forces Analysis
  • Table 8 Company Market Share Analysis
  • Table 9 Global Hormone Replacement Therapy (HRT) Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • Table 10 Hormone Replacement Therapy (HRT) Market, by Replacement Therapy, 2014 - 2025 (USD Billion)
  • Table 11 Hormone Replacement Therapy (HRT) Market, by Route of Administration, 2014 - 2025 (USD Billion)
  • Table 12 Hormone Replacement Therapy (HRT) Market, by Disease, 2014 - 2025 (USD Billion)
  • Table 13 Hormone Replacement Therapy (HRT) Market, by Geography, 2014 - 2025 (USD Billion)
  • Table 14 North America Hormone Replacement Therapy (HRT) Market, 2014 - 2025 (USD Billion)
  • Table 15 U.S. Hormone Replacement Therapy (HRT) Market, 2014 - 2025 (USD Billion)
  • Table 16 Canada Hormone Replacement Therapy (HRT) Market, 2014 - 2025 (USD Billion)
  • Table 17 Europe Hormone Replacement Therapy (HRT) Market, 2014 - 2025 (USD Billion)
  • Table 18 France Hormone Replacement Therapy (HRT) Market, 2014 - 2025 (USD Billion)
  • Table 19 Germany Hormone Replacement Therapy (HRT) Market, 2014 - 2025 (USD Billion)
  • Table 20 Asia Pacific Hormone Replacement Therapy (HRT) Market, 2014 - 2025 (USD Billion)
  • Table 21 China Hormone Replacement Therapy (HRT) Market, 2014 - 2025 (USD Billion)
  • Table 22 India Hormone Replacement Therapy (HRT) Market, 2014 - 2025 (USD Billion)
  • Table 23 Latin America Hormone Replacement Therapy (HRT) Market, 2014 - 2025 (USD Billion)
  • Table 24 MEA Hormone Replacement Therapy (HRT) Market, 2014 - 2025 (USD Billion)

List of Figures

  • Figure 1 Research Methodology
  • Figure 2 Research Process Flow Chart
  • Figure 3 Comparative Analysis, by Geography, 2016-2025 (Value %)
  • Figure 4 Regulatory Framework Analysis
  • Figure 5 Hormone Replacement Therapy (HRT) Market, by Replacement Therapy, 2014 - 2025 (USD Billion)
  • Figure 5 Hormone Replacement Therapy (HRT) Market, by Route of Administration, 2014 - 2025 (USD Billion)
  • Figure 5 Hormone Replacement Therapy (HRT) Market, by Disease, 2014 - 2025 (USD Billion)
  • Figure 6 Hormone Replacement Therapy (HRT) Market, by Geography, 2014 - 2025 (USD Billion)
目次
Product Code: AV181

Report Hightlights

The Hormone Replacement Therapy (HRT) market is estimated to represent a global market of USD 15.8 billion by 2017 with growth rate of 7.5%.

Market Dynamics

Menopause is a natural and inevitable event, defined as the final menstrual period. It requires a retrospective clinical diagnosis with ethnic and regional variations. Hormone replacement therapies (HRT) such as systemic estrogen (skin patch, gel, or cream) are considered to be the most effective treatment option in the treatment of menopausal night sweats and hot flashes. These therapies also ease vaginal symptoms of menopause such as itching, burning, and dryness. Due to this fact, women undergoing these therapies has increased considerably over the past few years.

As per the Rose Research Survey (April 2014), women accepting HT therapy has increased considerably, from 4.5 million in 2005 to around 5.0 million in 2014. In addition to this, the growth of this market is attributed to the rise in a number of women in menopausal age coupled with growing patient awareness. For example, according to the International Menopause Society, thousands of women reach menopause experience every day. On another hand, the high cost of therapies coupled with the high risk of adverse reactions posing a potential threat to this industry. For example, as per the study published in PLOS One journal in 2014, testosterone therapy in cardiac patients considerably increase the risk of heart attack.

Replacement Therapy Takeaway

In terms of replacement therapy, the market is categorized as Estrogen, Human Growth Hormone, Testosterone and Thyroid. Estrogen replacement therapy recorded USD 9.58 billion and is expected to soar owing to the approval of new products by the United States Food and Drug Association under this category. Some of the recommended estrogen doses for women with Primary Ovarian Insufficiency (POI) are 1.25 mg conjugated equine estrogen (CEE), 17b-estradiol 2 mg/day, and transdermal estradiol 75-100 mg/day.

Furthermore, Climara, Estradot, Divigel, Elestrin, and EstroGel are some of the commercially available transdermal estrogen products in the U.S. and Canada market by various manufacturers. On contrary, thyroid replacement therapy is considered to be the lowest revenue generating segment and is also pegged to register slowest growth rate i.e. 6.9% in terms of value. Levothyroxine (generic form of thyroxine) is a most commonly prescribed thyroid hormone replacement drug across the globe.

Route of Administration Takeaway

Route of administration is divided into Parenteral, Oral, Transdermal, and other. Among which, the parenteral segment recorded the highest share of the global market owing to its associated benefits. For example, parenteral administration of estrogen protect against the effects of andropause and reduce toxicity compared to the oral administration. The disease segment is divided into Male hypogonadism, Menopause, Hypothyroidism, Growth hormone deficiency, and others. Hypothyroidism is the lowest revenue generating segment, captured less than 15% share throughout the forecast period.

Regional Takeaway

Regionally, the market is divided into North America, Europe, Asia Pacific and Rest of the World. Of these, North America captured the highest share, 41.67% of the total market. Drugs such as Premarin, AndroGel, and Levothyroxine have been recorded to gain the maximum prescription within this region. However, Asia Pacific region represents one of the fastest growing regions, enjoying an annual average growth rate over 9.0%. Rising awareness levels coupled with increasing focus of healthcare and government on eradication of hormonal deficiencies are likely to establish a healthy platform for the industry growth in this region.

Key Vendor Takeaway

Companies such as Novo Nordisk, Amgen, Inc., Abbott, Eli Lily and Genentech are covered under research study. The industry experiences a high level of competition. In such fragmented landscape, key players are actively engaged in strategic collaborations to expand their market presence. For instance, in February 2015, Mylan Laboratories signed an agreement for the acquisition of Famy Care.

This acquisition has helped the company to increase its female health product portfolio inclusive of production of hormone replacement drugs, Intra-Uterine Devices (IUD), and contraceptives. Likewise, in December 2014, Pfizer collaborated with OPKO Health. As per the agreement, OPKO would be developing and marketing long-acting human growth hormone (hGH-CTP) (PF-06836922), whereas Pfizer would take care of the post-market studies and development costs.

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year - 2014 & 2016

Base Year - 2017

Estimated Year - 2018

Projected Year - 2025

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Hospitals

Government and Regional Agencies and Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

MARKET, BY REPLACEMENT THERAPY

Estrogen

Human Growth Hormone

Testosterone

Thyroid

MARKET, BY ROUTE OF ADMINISTRATION

Parenteral

Oral

Transdermal

Other

MARKET, BY DISEASE

Male Hypogonadism

Menopause

Hypothyroidism

Growth Hormone Deficiency

Others

MARKET, BY REGION

North America

U.S.

Canada

Europe

Germany

France

Rest of Europe

Asia Pacific

India

China

Rest of APAC

Rest of the World

Middle East and Africa

Latin America

TABLE OF CONTENTS

1. HORMONE REPLACEMENT THERAPY (HRT) MARKET OVERVIEW

  • 1.1. Study Scope
  • 1.2. Assumption and Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Key Market Facts
  • 2.2. Geographical Scenario
  • 2.3. Companies in the Market

3. HORMONE REPLACEMENT THERAPY (HRT) KEY MARKET TRENDS

  • 3.1. Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Future Trends

4. HORMONE REPLACEMENT THERAPY (HRT) INDUSTRY STUDY

  • 4.1. Porter's Analysis
  • 4.2. Market Attractiveness Analysis
  • 4.3. Regulatory Framework Analysis

5. HORMONE REPLACEMENT THERAPY (HRT) MARKET LANDSCAPE

  • 5.1. Market Share Analysis

6. HORMONE REPLACEMENT THERAPY (HRT) MARKET - BY REPLACEMENT THERAPY

  • 6.1. Overview
  • 6.2. Estrogen
    • 6.2.1. Overview
    • 6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 6.3. Human Growth Hormone
    • 6.3.1. Overview
    • 6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 6.4. Testosterone
    • 6.4.1. Overview
    • 6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 6.5. Thyroid
    • 6.5.1. Overview
    • 6.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)

7. HORMONE REPLACEMENT THERAPY (HRT) MARKET - BY ROUTE OF ADMINISTRATION

  • 7.1. Overview
  • 7.2. Parenteral
    • 7.2.1. Overview
    • 7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 7.3. Oral
    • 7.3.1. Overview
    • 7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 7.4. Transdermal
    • 7.4.1. Overview
    • 7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 7.5. Other
    • 7.5.1. Overview
    • 7.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)

8. HORMONE REPLACEMENT THERAPY (HRT) MARKET - BY DISEASE

  • 8.1. Overview
  • 8.2. Male Hypogonadism
    • 8.2.1. Overview
    • 8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 8.3. Menopause
    • 8.3.1. Overview
    • 8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 8.4. Hypothyroidism
    • 8.4.1. Overview
    • 8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 8.5. Growth Hormone Deficiency
    • 8.5.1. Overview
    • 8.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 8.6. Others
    • 8.6.1. Overview
    • 8.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)

9. HORMONE REPLACEMENT THERAPY (HRT) MARKET- BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 9.2.3. U.S.
    • 9.2.3.1. Overview
    • 9.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 9.2.4. Canada
    • 9.2.4.1. Overview
    • 9.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 9.3.3. France
    • 9.3.3.1. Overview
    • 9.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 9.3.4. Germany
    • 9.3.4.1. Overview
    • 9.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 9.3.5. Rest of Europe
    • 9.3.5.1. Overview
    • 9.3.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 9.4.3. China
    • 9.4.3.1. Overview
    • 9.4.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 9.4.4. India
    • 9.4.4.1. Overview
    • 9.4.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 9.4.5. Rest of APAC
    • 9.4.5.1. Overview
    • 9.4.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
  • 9.5. Rest of the World
    • 9.5.1. Overview
    • 9.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 9.5.3. Latin America
    • 9.5.3.1. Overview
    • 9.5.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)
    • 9.5.4. Middle East and Africa
    • 9.5.4.1. Overview
    • 9.5.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2014 - 2025, (US$ Billion)

10. KEY VENDOR ANALYSIS

  • 10.1. Novo Nordisk
    • 10.1.1. Company Overview
    • 10.1.2. SWOT Analysis
    • 10.1.3. Key Developments
  • 10.2. Amgen, Inc.
    • 10.2.1. Company Overview
    • 10.2.2. SWOT Analysis
    • 10.2.3. Key Developments
  • 10.3. Abbott
    • 10.3.1. Company Overview
    • 10.3.2. SWOT Analysis
    • 10.3.3. Key Developments
  • 10.4. Eli Lily & Company
    • 10.4.1. Company Overview
    • 10.4.2. SWOT Analysis
    • 10.4.3. Key Developments
  • 10.5. Genentech
    • 10.5.1. Company Overview
    • 10.5.2. SWOT Analysis
    • 10.5.3. Key Developments

Client can request additional company profiling as per specific requirements

11. 360 DEGREE ANALYSTVIEW

12. APPENDIX

  • 12.1. Research Methodology
  • 12.2. Abbreviations
  • 12.3. Disclaimer
  • 12.4. Contact Us
Back to Top